PIA
DNLI icon

Piedmont Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Piedmont Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-294
Closed -$4K – 1378
2018
Q2 		$4K Buy
+294
New +$5.54K ﹤0.01% 2224

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Piedmont Investment Advisors's DNLI Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Denali Therapeutics (DNLI) in Q3 2018, closing a stake of 294 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in DNLI in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 78 funds tracked by Wall St. Rank hold DNLI as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Denali Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 294 Denali Therapeutics shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Denali Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Denali Therapeutics position peaked at $4K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.